Key opportunities in the buprenorphine patch market include enhancing opioid stewardship, leveraging digital prescribing, securing robust supply chains, and aligning clinical protocols with payer and ...
September 28, 2010 (Las Vegas, Nevada) — A transdermal application system containing the partial μ-opioid receptor agonist buprenorphine showed analgesic efficacy in the treatment of low back pain in ...
ICD is much more common than ACD among users of the buprenorphine TTS. During the clinical development of the buprenorphine TTS, three double-blind placebocontrolled parallel group studies and one ...
Buprenorphine is a medication approved for pain and opioid dependence. New findings published in The American Journal on Addictions indicate that a transmucosal dose (which dissolves in the mouth) of ...
18.5. Alvogen, Inc. 18.6. Amneal Pharmaceuticals, Inc. 18.7. Camber Pharmaceuticals, Inc. 18.8. Indivior UK Limited 18.9. Lupin Limited 18.10. Purdue Pharma L.P. 18. ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results